miREIA is a novel, immunoassay-based method of miRNA quantification which involves hybridization of miRNA isolated from a patient sample to complementary biotinylated DNA oligonucleotide probe. The DNA/RNA hybrids are then captured by a microtiter plate-immobilized monoclonal antibody specific to perfectly matched DNA/miRNA hybrids. Next steps are copying standard ELISA protocols.
The assay can be run on common immunoassay equipment, is compatible with standard clinical workflow, does not require amplification steps and results are obtained in less than three hours including miRNA profiling.
BioVendor develops immunoassays for the detection of newly identified protein markers in samples of human or animal origin. This effort has resulted in the release of many products that are unique to the market. The development of new kits is targeted to research groups within the international scientific community as well as to clinical laboratory applications.
BioVendor's use of modern immunoassay formats has enabled high assay sensitivity, with an emphasis on superior analytical characteristics and user-friendly kit performance.
BioVendor is continually developing products and services that are aimed at meeting the needs of our diverse customer base. We offer user-friendly immunoassays for customers requiring fully equipped kits, as well as ELISA development kits – PENTASET for those who prefer the advantage of kits enabling both customer modification of the immunoassay and cost effective measurement of a large specimen cohort.
Last but not least, we can help researchers with limited access to laboratory analysis and BioVendor offers measurement of clients samples with our analytical service BATS.
From the first description in 1993, the small regulatory molecules, called microRNA or miRNA, become emerging biomarkers for research in all fields of medical and biological sciences. This new miRNA regulatory domain empowers translational R&D, identifies novel disease biomarkers in biofluids and tissues and develops non-invasive screening and diagnostic tests.
BioVendor offers specific technologies based on patented RT-qPCR for sensitive detection and quantification of miRNA molecules. The technologies use multiplex detection format already used in life sciences research and clinical diagnostic applications.
BioVendor Group is an international diagnostics company with its headquarters in Brno, Czech Republic.
BioVendor provides a broad range of IVD technologies and capabilities including, in-house development and manufacturing of immunoassays and molecular diagnostics for the clinical market, as well as a wide offering for the Life Sciences market.
The core of the portfolio consists of immunoassays in several formats, both single-test and multiplexed. The portfolio is focused on infectious serology, autoimmunity, endocrinology, and newly-discovered biomarkers.
Since its establishment in 1992, BioVendor has placed high importance on innovation and value brought to customers via providing diagnostics solutions. Recent examples include, fully automated ELISA platform, proprietary microarray solution, Next Generation Sequencing kits, and proprietary miRNA immunoassays.
BioVendor is committed to its strategy to grow internationally. BioVendor has an extensive track record of acquisitions including, TestLine Clinical Diagnostics (Czech Republic), ViennaLab Diagnostics (Austria), Oxford Biosystems (UK), and most recently in September 2017, DIAsource Immuno-Assays (Belgium).